Even therecent published trials of dipeptidyl peptidase-4 inhibitors in patients with type 2diabetes and high cardiovascular risk did not show a reduction in cardiovascularevents [11–13], but there was a concernregarding heart failure incidence in two of the trials [12,90]. The gene discussed is DPP4; the disease is heart failure.